Carol M. Gatton Chairman of Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Digestive Diseases, Imperial College, London, UK.
J Hepatol. 2022 Jun;76(6):1279-1290. doi: 10.1016/j.jhep.2022.03.025.
In recent years, there have been important advances in our understanding of alcohol-associated hepatitis (AH), which have occurred in parallel with a surge in clinical trial activity. Meanwhile, the broader medical field has seen a transformation in care paradigms based on emerging digital technologies. This review focuses on breakthroughs in our understanding of AH and how these breakthroughs are leading to new paradigms for biomarker discovery, clinical trial activity, and care models for patients. It portends a future in which multimodal data from genetic, radiomic, histologic, and environmental sources can be integrated and synthesised to generate personalised biomarkers and therapies for patients with AH.
近年来，我们对酒精相关性肝炎（AH）的认识有了重要的进展，这与临床试验活动的激增是并行的。与此同时，更广泛的医疗领域也出现了基于新兴数字技术的护理模式转变。本综述重点介绍了我们对 AH 的认识的突破，以及这些突破如何为生物标志物发现、临床试验活动和患者护理模式带来新的范例。这预示着未来可以整合来自遗传、放射组学、组织学和环境源的多模态数据，为 AH 患者生成个性化的生物标志物和治疗方法。
